GlassScriptPhysician profile
Akimyo C Russell
NPI 1295928570
$3,742.82
in general payments reported to CMS, 2019-2025
24 companies · $889 in 2025
The $889 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,111 · 2022: $811 · 2023: $493 · 2024: $439 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801 · Consulting Fee: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.40 |
| Consulting Fee | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $603.22 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $525.21 | 2021-2025 | Cuvitru, Takhzyro |
| Genzyme Corporation | $466.12 | 2021-2025 | |
| Pfizer INC. | $414.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $333.98 | 2021-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $288.41 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $208.46 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $187.11 | 2021-2025 | |
| Grifols USA, LLC | $152.16 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Alk-Abello, INC | $116.43 | 2021-2025 | Odactra, Ragwitek, Grastek |
| Csl Behring | $93.61 | 2021-2025 | Haegarda |
| Amgen INC. | $59.18 | 2025 | Tezspire |
| Kowa Pharmaceuticals America, INC. | $34.20 | 2022 | |
| Organon LLC | $30.00 | 2023 | Nexplanon |
| Optinose US, INC. | $28.53 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $26.32 | 2025 | Neffy |
| Lundbeck LLC | $26.03 | 2023 | Vyepti |
| Lilly USA, LLC | $24.38 | 2024 | Jardiance, Zepbound |
| Kaleo, INC. | $23.53 | 2021 | |
| Mylan Specialty L.P. | $23.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.26 | 2021 | |
| Intersect Ent, INC. | $21.23 | 2022 | |
| Adma Biomanufacturing LLC | $19.72 | 2025 | |
| Horizon Therapeutics Plc | $16.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akimyo Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.